Your browser doesn't support javascript.
loading
Five-year survival in patients with nodular and superficial spreading melanomas in the US population.
Allais, Blair S; Beatson, Meghan; Wang, Hongkun; Shahbazi, Shandiz; Bijelic, Lana; Jang, Sekwon; Venna, Suraj.
Afiliación
  • Allais BS; Washington University Department of Dermatology, Washington, DC. Electronic address: blairallais@gwu.edu.
  • Beatson M; Memorial Sloan Kettering Cancer Center Department of Medicine, New York, NY.
  • Wang H; Georgetown University Departments of Biostatistics, Bioinformatics, and Biomathematics, Washington, DC.
  • Shahbazi S; Georgetown University Departments of Medicine, Washington, DC.
  • Bijelic L; Hospital de Sant Joan Despi Moises Broggi, Barcelona, Spain.
  • Jang S; University of Virginia School of Medicine, Charlottesville, VA; Inova Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, VA.
  • Venna S; University of Virginia School of Medicine, Charlottesville, VA; Inova Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, VA.
J Am Acad Dermatol ; 84(4): 1015-1022, 2021 Apr.
Article en En | MEDLINE | ID: mdl-33253834
ABSTRACT

BACKGROUND:

Although superficial spreading melanomas (SSM) are diagnosed as thinner lesions, nodular melanomas (NM) have a more rapid growth rate and are biologically more aggressive compared with other histologic subtypes.

OBJECTIVE:

To determine the difference in 5-year relative survival in patients with NM and SSM at the same Breslow depth and TNM stage.

METHODS:

A population-based cross-sectional analysis compared the 5-year relative survival of patients with NM and SSM using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)∗Stat software (version 8.2.1-8.3.5). Chi-square tests compared the proportions, and Kaplan-Meier method with Z-score compared 5-year relative survival.

RESULTS:

For patients receiving a diagnosis between 2004 and 2009, 5-year relative survival was lower in NM compared with SSM (53.7% vs 87.3%; Z score, -41.35; P < .001). Similarly, for patients receiving a diagnosis between 2010 and 2015, 5-year relative survival was lower in NM compared with SSM (61.5% vs 89.7%; Z score, -2.7078; P < .01). Subgroup analyses showed inferior survival in NM in T1b, and survival differences remained significant after excluding patients with nodal or distant metastases.

CONCLUSIONS:

Five-year relative survival is worse in NM compared with SSM especially in T1b, T2a, and T2b melanomas. Melanoma subtype should be taken into consideration when making treatment recommendations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Am Acad Dermatol Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Am Acad Dermatol Año: 2021 Tipo del documento: Article